ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 583,74
-0,64%
Dow Jones
40 211,72
0,53%
DAX
18 491,92
-0,58%
Brent Oil
83,61
-0,87%
Bitcoin
62 735,97
-3,26%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
01/11/201821h03GlobeNewswire Inc.Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American S...NASDAQ:PTLAPortola Pharmaceuticals Inc
31/10/201823h30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/10/201814h30GlobeNewswire Inc.Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2...NASDAQ:PTLAPortola Pharmaceuticals Inc
18/10/201821h20Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
18/10/201800h47Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/10/201822h39Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/10/201815h05GlobeNewswire Inc.Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growin...NASDAQ:PTLAPortola Pharmaceuticals Inc
25/09/201822h38GlobeNewswire Inc.Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of...NASDAQ:PTLAPortola Pharmaceuticals Inc
20/09/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Names Scott Garland President and Chief Executive OfficerNASDAQ:PTLAPortola Pharmaceuticals Inc
12/09/201800h06GlobeNewswire Inc.U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa ...NASDAQ:PTLAPortola Pharmaceuticals Inc
07/09/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Announces Executive Leadership ChangeNASDAQ:PTLAPortola Pharmaceuticals Inc
06/09/201800h15GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
31/08/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa ProcessNASDAQ:PTLAPortola Pharmaceuticals Inc
30/08/201814h00GlobeNewswire Inc.Portola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
09/08/201822h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/08/201814h01GlobeNewswire Inc.Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
09/08/201814h00GlobeNewswire Inc.Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources OfficerNASDAQ:PTLAPortola Pharmaceuticals Inc
03/08/201814h00GlobeNewswire Inc.U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ An...NASDAQ:PTLAPortola Pharmaceuticals Inc
02/08/201814h30GlobeNewswire Inc.Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 201...NASDAQ:PTLAPortola Pharmaceuticals Inc
27/07/201814h24GlobeNewswire Inc.European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following AppealNASDAQ:PTLAPortola Pharmaceuticals Inc
03/07/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
25/06/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical OperationsNASDAQ:PTLAPortola Pharmaceuticals Inc
08/06/201823h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/06/201812h18Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/06/201822h30GlobeNewswire Inc.Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
04/06/201822h30GlobeNewswire Inc.Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
04/06/201814h30GlobeNewswire Inc.New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor C...NASDAQ:PTLAPortola Pharmaceuticals Inc
09/05/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
04/05/201803h49GlobeNewswire Inc.U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa InhibitorsNASDAQ:PTLAPortola Pharmaceuticals Inc
02/05/201815h33GlobeNewswire Inc.Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

NASDAQ
RCACW
Revelstone Capital Acqui...
BIT
GG2DN9
GB00BSG2DN94 20270610 4....
LSE
0RAR
Stratec Biomedical
LSE
0HN5
Big Lots
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés